[go: up one dir, main page]

MXPA06002666A - Cristal de compuesto heterociclico. - Google Patents

Cristal de compuesto heterociclico.

Info

Publication number
MXPA06002666A
MXPA06002666A MXPA06002666A MXPA06002666A MXPA06002666A MX PA06002666 A MXPA06002666 A MX PA06002666A MX PA06002666 A MXPA06002666 A MX PA06002666A MX PA06002666 A MXPA06002666 A MX PA06002666A MX PA06002666 A MXPA06002666 A MX PA06002666A
Authority
MX
Mexico
Prior art keywords
methyl
degree
crystals
crystal
oxazol
Prior art date
Application number
MXPA06002666A
Other languages
English (en)
Inventor
Tetsuji Harabe
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of MXPA06002666A publication Critical patent/MXPA06002666A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

El proposito principal de la invencion es proporcionar un nuevo cristal especifico del acido 2-metil- c-5-[4-[5-metil- 2-(4-metilfenil)-1, 3-oxazol-4 -il]butil]-1, 3-dioxano- r-2-carboxilico. La invencion incluye, por ejemplo, un cristal del acido 2-metil-c- 5-[4-[5-metil- 2-(4-metilfenil)-1, 3-oxazol-4 -il]butil]-1, 3-dioxano-r -2-carboxilico, la cual tiene picos a los angulos de difraccion de al menos 12.4??, 17.1??, y 20.8 degree en un espectro de difraccion de rayos X en polvo, y un agente preventivo o terapeutico que comprende el cristal como un ingrediente activo para su uso en las enfermedades de las arterias coronarias, infarto cerebral, hiperlipemia, arterioesclerosis, diabetes mellitus, hipertension, u obesidad.
MXPA06002666A 2003-09-12 2004-09-10 Cristal de compuesto heterociclico. MXPA06002666A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003320556 2003-09-12
PCT/JP2004/013209 WO2005026160A1 (ja) 2003-09-12 2004-09-10 複素環化合物の結晶

Publications (1)

Publication Number Publication Date
MXPA06002666A true MXPA06002666A (es) 2006-06-06

Family

ID=34308606

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06002666A MXPA06002666A (es) 2003-09-12 2004-09-10 Cristal de compuesto heterociclico.

Country Status (11)

Country Link
US (1) US20070027198A1 (es)
EP (1) EP1666479A1 (es)
JP (1) JPWO2005026160A1 (es)
KR (1) KR20060123087A (es)
CN (1) CN1849317A (es)
AU (1) AU2004272428A1 (es)
BR (1) BRPI0414274A (es)
CA (1) CA2538425A1 (es)
MX (1) MXPA06002666A (es)
RU (1) RU2006111451A (es)
WO (1) WO2005026160A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102014103827A1 (de) * 2014-03-20 2015-09-24 Thyssenkrupp Ag Antriebsvorrichtung zum Antrieb eines Werkzeugschiebers in einer Falzanlage

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2410382A1 (en) * 2000-05-26 2002-11-25 Nippon Shinyaku Co., Ltd. Heterocyclic compounds

Also Published As

Publication number Publication date
BRPI0414274A (pt) 2006-11-07
JPWO2005026160A1 (ja) 2007-11-08
WO2005026160A1 (ja) 2005-03-24
AU2004272428A1 (en) 2005-03-24
RU2006111451A (ru) 2006-07-27
EP1666479A1 (en) 2006-06-07
CN1849317A (zh) 2006-10-18
CA2538425A1 (en) 2005-03-24
US20070027198A1 (en) 2007-02-01
KR20060123087A (ko) 2006-12-01

Similar Documents

Publication Publication Date Title
DE60325074D1 (de) Kristall für ein orales, festes arzneimittel, und ein orales, festes arnzeimittel zur behandlung von dysurie, das diesen enthält
NO20060636L (no) Trisubstituerte aryl og heteroarylderivater som modulatorer av metabolisme og profylakse og behandling av lidelser relatert til dette
IL160945A (en) 4, 5 - diarylthiazole - 2 - carboxamides having cb1 - antagonistic, agonistic or partial agonistic activity and use thereof for the preparation of pharmaceutical compositions
WO2005044192A3 (en) Triazole compounds and uses related thereto
CA2474578A1 (en) Novel pyridin- and pyrimidin-derivatives
DE60226764D1 (de) Substituierte heteroarylalkansäure und ihre verwendung als inhibitoren der aldose reductase
NO20054852L (no) GFAT inhibitorer
NO20051600L (no) 1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer
NO20050828L (no) lndol-3-svovelderivater
NO20051103L (no) Indol-3-karboksamider som Glukokinase-(GK)-Aktivatorer
TW200505919A (en) DPP-IV inhibitors
CA2464068A1 (en) .alpha.-form or .beta.-form crystal of (r)-2-(2-aminothiazol-4yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl)acetanilide
NO20083114L (no) Polysykliske indazolderivater som er ERK-inhibitorer
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
CA2472954A1 (en) Aza-arylpiperazines
CA2454022A1 (en) Use of 4-[(4-thiazolyl)phenoxy]alkoxy-benzamidine derivatives for treatment of osteoporosis
NO20075399L (no) Benzimidazolerivat og anvendelse derav
EA200101121A1 (ru) Полиморф 5-[4-[2-(n-метил-n-(2-пиридил) амино) этокси] бензил] тиазолидин-2,4-диона, соли малеиновой кислоты
EA200101119A1 (ru) Новый фармацевтический препарат
WO2007015999A3 (en) Process for synthesizing a substituted pyrazole
NO20052182L (no) Nye forbindelser
NO20060146L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
MX2009005619A (es) Formas poliformicas del deferasirox (icl670a).
MXPA06002666A (es) Cristal de compuesto heterociclico.
NO20025659D0 (no) Heterocykliske forbindelser